Episode Details

Axsome Therapeutics is exploding on the scene with a trio of CNS drugs—Auvelity for Alzheimer’s agitation and depression, Sunosi for sleepiness, and Symbravo for migraines—driving its stock up 200% in three years. With a massive sales force pushing Auvelity and efforts to expand insurance coverage for Symbravo, the company is aggressively commercializing its approved therapies. Beyond that, a strong pipeline includes AXS-12 for narcolepsy and late-stage candidates for ADHD, depression, and fibromyalgia, hinting at future revenue giants. While the “millionaire maker” hype is overblown—$1,000 could only net $6,000 at 500% gain, requiring unrealistic valuation—Axsome’s $300M cash reserve and early-stage growth trajectory position it for sustained expansion as it builds toward profitability.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/2fb9680af47960c9